- Research team uses Delphi process for the first time to identify ideal cannabis dosing guidelines.
- After several rounds of voting, the ‘global task force’ created three separate dosing protocols.
- RYAH Group’s suite of precision dosing devices provide a practical way to safely execute these — or any — recommended dosing guidelines.
Dosing recommendations are critical in any health treatments, but where cannabis is concerned, dosing levels have been tricky to identify. A recent blog from RYAH Group (CSE: RYAH) notes that a team of more than 20 cannabis experts have published consensus recommendations for dosing and administration of medical cannabis to treat chronic pain (https://cnw.fm/FLezW). RYAH is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments.
“Despite hundreds of thousands of patients legally using medical cannabis to treat a broad spectrum of conditions, it remains frustratingly difficult to dose,” the Sept. 8 article states. “There are no official guidelines or dosing schedules. In large part, patients experiment independently, with information found online or based on vague suggestions from friends.
“Physicians, researchers, and lawmakers have struggled to craft policies around cannabis dosage guidelines,” the blog continued. “But, as medical cannabis earns more acceptance across the national and international health care community, there have been renewed attempts to settle on safe and standardized dosage recommendations.”
The article goes on to report that in a renewed attempt to identify clear, scientifically supported dosing recommendations, researchers applied the Delphi process to reach a dosage consensus regarding a specific condition; the team chose to focus on chronic pain. The researchers utilized the Delphi process, a systematic, interactive way of gaining opinions or agreement from a panel of independent experts, typically through surveys or questionnaires of some sort, to determine cannabis dosing (https://cnw.fm/qmYty). Results of the group’s efforts were published in the “Journal of Cannabis Research.”
The paper noted that “the modified Delphi process has been used extensively in health care settings to provide consensus-based recommendations on important clinical questions where randomized control trial data is lacking.” Cannabis dosing seemed perfectly suited to this approach.
“After several rounds of voting, the ‘global task force’ created three separate dosing protocols: routine administration, conservative administration, and rapid administration,” the RYAH blog noted. “Each is designed to ease a patient treating chronic pain into medical cannabis and treatment with THC if needed.
“Dosing guidelines like [these] just one-half of the equation,” the article continued. “The other half is the delivery mechanism. Patients need a reliable way to receive consistent and measurable doses, to adhere to their treatment protocol. Physicians also need a way to monitor patient titration and dose size.”
Enter RYAH Group.
RYAH Group’s suite of precision intake control and management devices provides a practical way to execute these — or any — volume control guidelines safely. The RYAH Smart Patch, Inhaler, and Pen enable patients and physicians to control their medicine, the specific administration volume, and the protocol behind the treatment. In addition, detailed analytics provided by these RYAH devices help determine which intake volumes are working and what needs adjusting, and a patient’s progress in their treatment. It’s the data-driven approach to plant-based medicine desperately needed to help patients reach their goals faster.
“We want to create useful technology that collects, analyzes, and leverages objective data on therapeutic plant usage,” the company states. “A holistic approach to plant treatment is now possible thanks to RYAH products. Using smart devices, artificial intelligence, and an integrated platform, patients and doctors can stay on top of their prescriptions in a way that is both safe and seamless.”
For more information, visit the company’s website at www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://cnw.fm/RYAH
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.